{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:58:29Z","timestamp":1793055509999,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","award":["NIHR300160"],"award-info":[{"award-number":["NIHR300160"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Current methods for modelling spillover effects on carers in economic evaluation include four main methods: (absolute) utilities, disutilities, increments and multipliers. Each of these approaches assumes that the spillover effect is one-dimensional. We aimed to develop a new approach that better reflects the complexity of caring and the nuances of how a new treatment may impact the caregiver. We propose a new method based on the established concepts of the \u2018family effect\u2019 (or caring about someone) and the \u2018caregiving effect\u2019 (providing care for someone). These effects can be disentangled through analysis of carer-patient dyads or using patient and carer (dis)utilities and estimates from the literature. We consider case studies in Duchenne Muscular Dystrophy, Spinal Muscular Atrophy and Alzheimer\u2019s Disease. Our approach models a small carer health-related quality of life (HRQoL) gain for each intervention, whereas the utility approach consistently models a substantial carer HRQoL gain, and the disutility approach models a carer HRQoL loss in two case studies. Our method allows explicit consideration of the benefits to carers of extending patient survival or improving patient health, with the negative HRQoL impact of increased caregiving burden. We propose that our method can be used with published data at present, and further research should analyse the family and caregiving effects in different conditions.<\/jats:p>","DOI":"10.1007\/s40273-025-01540-w","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:18:16Z","timestamp":1762003096000},"page":"13-23","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Caring for and Caring about in Economic Evaluation: Modelling the Family and Caregiving Effects"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1002-022X","authenticated-orcid":false,"given":"Becky","family":"Pennington","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6609-4287","authenticated-orcid":false,"given":"Sarah","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9067-3422","authenticated-orcid":false,"given":"Holly","family":"Cranmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"1540_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s40273-022-01164-4","volume":"40","author":"B Pennington","year":"2022","unstructured":"Pennington B, Eaton J, Hatswell AJ, et al. Carers\u2019 health-related quality of life in global health technology assessment: guidance, case studies and recommendations. Pharmacoeconomics. 2022;40:837\u201350.","journal-title":"Pharmacoeconomics"},{"key":"1540_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40258-023-00834-4","volume":"22","author":"B Pennington","year":"2024","unstructured":"Pennington B, Al-Janabi H. Modelling informal carers\u2019 health-related quality of life: challenges for economic evaluation. Appl Health Econ Health Policy. 2024;22:9\u201316.","journal-title":"Appl Health Econ Health Policy"},{"key":"1540_CR3","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40273-023-01331-1","volume":"42","author":"R Lamsal","year":"2024","unstructured":"Lamsal R, Yeh EA, Pullenayegum E, et al. A systematic review of methods used by pediatric cost-utility analyses to include family spillover effects. Pharmacoeconomics. 2024;42:199\u2013217.","journal-title":"Pharmacoeconomics"},{"key":"1540_CR4","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.jval.2020.05.017","volume":"23","author":"BM Pennington","year":"2020","unstructured":"Pennington BM. Inclusion of carer health-related quality of life in National Institute for Health and Care Excellence appraisals. Value Health. 2020;23:1349\u201357.","journal-title":"Value Health"},{"key":"1540_CR5","doi-asserted-by":"publisher","unstructured":"Kanters TA, van Hezik-Wester V, Boateng A, et al. Including carer health-related quality of life in NICE health technology assessments in the United Kingdom. Health Econ Policy Law. 2024: 1\u201313. https:\/\/doi.org\/10.1017\/S1744133124000124","DOI":"10.1017\/S1744133124000124"},{"key":"1540_CR6","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40273-021-01098-3","volume":"40","author":"SE Grimm","year":"2022","unstructured":"Grimm SE, Witlox W, Wolff R, et al. Mogamulizumab for previously treated mycosis fungoides and sezary syndrome: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2022;40:509\u201318.","journal-title":"Pharmacoeconomics"},{"key":"1540_CR7","unstructured":"National Institute for Health and Care Excellence. Givinostat for treating Duchenne muscular dystrophy in people 6 years and over. 2025. https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta11373"},{"key":"1540_CR8","unstructured":"National Institute for Health and Care Excellence. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer\u2019s disease. 2025. https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta11220"},{"key":"1540_CR9","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s40273-023-01316-0","volume":"41","author":"DJ Mott","year":"2023","unstructured":"Mott DJ, Schirrmacher H, Al-Janabi H, et al. Modelling spillover effects on informal carers: the carer QALY trap. Pharmacoeconomics. 2023;41:1557\u201361.","journal-title":"Pharmacoeconomics"},{"key":"1540_CR10","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s40273-023-01324-0","volume":"41","author":"JM Tilford","year":"2023","unstructured":"Tilford JM, Tarlan A. The carer QALY trap and altruism in economic evaluations. Pharmacoeconomics. 2023;41:1553\u20135.","journal-title":"Pharmacoeconomics"},{"key":"1540_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.jhealeco.2004.12.002","volume":"24","author":"A Basu","year":"2005","unstructured":"Basu A, Meltzer D. Implications of spillover effects within the family for medical cost-effectiveness analysis. J Health Econ. 2005;24:751\u201373.","journal-title":"J Health Econ"},{"key":"1540_CR12","unstructured":"National Institute for Health and Care Excellence. Risdiplam for treating spinal muscular atrophy. 2021. https:\/\/www.nice.org.uk\/guidance\/ta755"},{"key":"1540_CR13","doi-asserted-by":"publisher","first-page":"1604025","DOI":"10.3389\/ijph.2021.1604025","volume":"66","author":"M Zanganeh","year":"2021","unstructured":"Zanganeh M, Adab P, Li B, et al. Cost-effectiveness of a school-and family-based childhood obesity prevention programme in china: the \u201cCHIRPY DRAGON\u201d cluster-randomised controlled trial. Int J Public Health. 2021;66:1604025.","journal-title":"Int J Public Health"},{"key":"1540_CR14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1177\/0272989X15605094","volume":"36","author":"H Al-Janabi","year":"2016","unstructured":"Al-Janabi H, van Exel J, Brouwer W, et al. A framework for including family health spillovers in economic evaluation. Med Decis Mak. 2016;36:176\u201386.","journal-title":"Med Decis Mak"},{"key":"1540_CR15","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/hec.3259","volume":"25","author":"H Al-Janabi","year":"2016","unstructured":"Al-Janabi H, Van Exel J, Brouwer W, et al. Measuring health spillovers for economic evaluation: a case study in meningitis. Health Econ. 2016;25:1529\u201344.","journal-title":"Health Econ"},{"key":"1540_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2019.112382","volume":"235","author":"H Al-Janabi","year":"2019","unstructured":"Al-Janabi H, McLoughlin C, Oyebode J, et al. Six mechanisms behind carer wellbeing effects: a qualitative study of healthcare delivery. Soc Sci Med. 2019;235:112382.","journal-title":"Soc Sci Med"},{"key":"1540_CR17","unstructured":"The Dental and Pharmaceutical Benefits Agency (TLV). Calculation and payment. 2022. https:\/\/www.tlv.se\/in-english\/reports\/arkiv\/2023-01-27-calculation-and-payment.-continued-study-on-evaluation-methods-and--payment-models-for-new-medicines-such-as--atmps-and-precision-medicine----2022.html"},{"key":"1540_CR18","doi-asserted-by":"publisher","unstructured":"Santini S, Socci M, D'Amen B, et al. Positive and Negative Impacts of Caring among Adolescents Caring for Grandparents. Results from an Online Survey in Six European Countries and Implications for Future Research, Policy and Practice. Int J Environ Res Public Health. 2020;17(18):6593. https:\/\/doi.org\/10.3390\/ijerph17186593","DOI":"10.3390\/ijerph17186593"},{"key":"1540_CR19","volume-title":"Towards a feminist theory of care. Circles of care","author":"B Fisher","year":"1990","unstructured":"Fisher B, Tronto J. Towards a feminist theory of care. Circles of care. Albany: State University of New York Press; 1990."},{"key":"1540_CR20","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jhealeco.2010.05.003","volume":"29","author":"A Bobinac","year":"2010","unstructured":"Bobinac A, van Exel NJ, Rutten FF, et al. Caring for and caring about: disentangling the caregiver effect and the family effect. J Health Econ. 2010;29:549\u201356.","journal-title":"J Health Econ"},{"key":"1540_CR21","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1177\/0272989X10374212","volume":"31","author":"A Bobinac","year":"2011","unstructured":"Bobinac A, van Exel NJ, Rutten FF, et al. Health effects in significant others: separating family and care-giving effects. Med Decis Making. 2011;31:292\u20138.","journal-title":"Med Decis Making"},{"key":"1540_CR22","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jval.2024.08.004","volume":"28","author":"BM Pennington","year":"2025","unstructured":"Pennington BM, Alava MH, Strong M. Unpaid caring and health-related quality of life: longitudinal analysis of understanding society (the UK household longitudinal survey). Value Health. 2025;28:138\u201347.","journal-title":"Value Health"},{"key":"1540_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2021.114081","volume":"281","author":"SH Han","year":"2021","unstructured":"Han SH, Kim K, Burr JA. Take a sad song and make it better: spousal activity limitations, caregiving, and depressive symptoms among couples. Soc Sci Med. 2021;281:114081.","journal-title":"Soc Sci Med"},{"key":"1540_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.alcr.2023.100579","volume":"58","author":"SH Han","year":"2023","unstructured":"Han SH. Revisiting the caregiver stress process: does family caregiving really lead to worse mental health outcomes? Adv Life Course Res. 2023;58:100579.","journal-title":"Adv Life Course Res"},{"key":"1540_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40273-024-01367-x","volume":"42","author":"E Landfeldt","year":"2024","unstructured":"Landfeldt E, Sandhu H. Economic evaluations of treatments for Duchenne muscular dystrophy: the caregiver QALY trap. Pharmacoeconomics. 2024;42:475\u20138.","journal-title":"Pharmacoeconomics"},{"key":"1540_CR26","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40273-024-01452-1","volume":"43","author":"B Pennington","year":"2025","unstructured":"Pennington B, Hernandez Alava M, Strong M. How does bereavement affect the health-related quality of life of household members who do and do not provide unpaid care? Difference-in-differences analyses using the UK household longitudinal survey. Pharmacoeconomics. 2025;43:389\u2013402.","journal-title":"Pharmacoeconomics"},{"key":"1540_CR27","doi-asserted-by":"publisher","unstructured":"Henry E, Cullinan J. Maternal Mental Health Spillovers From Child Illness and Disability: A Dynamic Panel Analysis. Value Health. 2025;28(3):348-357. https:\/\/doi.org\/10.1016\/j.jval.2024.09.011","DOI":"10.1016\/j.jval.2024.09.011"},{"key":"1540_CR28","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s40273-019-00789-2","volume":"37","author":"CC Brown","year":"2019","unstructured":"Brown CC, Tilford JM, Payakachat N, et al. Measuring health spillover effects in caregivers of children with autism spectrum disorder: a comparison of the EQ-5D-3L and SF-6D. Pharmacoeconomics. 2019;37:609\u201320.","journal-title":"Pharmacoeconomics"},{"key":"1540_CR29","unstructured":"National Institute for Health and Care Excellence. Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene. 2023.  https:\/\/www.nice.org.uk\/guidance\/hst22"},{"key":"1540_CR30","unstructured":"National Institute for Health and Care Excellence. Onasemnogene abeparvovec for treating spinal muscular atrophy. 2023.  https:\/\/www.nice.org.uk\/guidance\/hst24"},{"key":"1540_CR31","doi-asserted-by":"publisher","unstructured":"Handels R, Herring WL, Grimm S, et al. New IPECAD Open-Source Model Framework for the Health Technology Assessment of Early Alzheimer's Disease Treatment: Development and Use Cases. Value Health. 2025;28(4):511-518. https:\/\/doi.org\/10.1016\/j.jval.2024.07.009","DOI":"10.1016\/j.jval.2024.07.009"},{"key":"1540_CR32","unstructured":"Hern\u00e1ndez Alava MP, S.; Wailoo, A. Estimating EQ-5D by age and sex for the UK. Report by the decision support unit. 2022.  https:\/\/www.sheffield.ac.uk\/nice-dsu\/methods-development\/estimating-eq-5d"},{"key":"1540_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-025-03937-8","author":"PA Powell","year":"2025","unstructured":"Powell PA, Carlton J, Peasgood T, et al. Understanding the health-related quality of life impacts of caring for children and adolescents with rare progressive life-limiting conditions: key challenges and future research priorities. Qual Life Res. 2025. https:\/\/doi.org\/10.1007\/s11136-025-03937-8.","journal-title":"Qual Life Res"},{"key":"1540_CR34","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s11136-004-3305-2","volume":"14","author":"JM Tilford","year":"2005","unstructured":"Tilford JM, Grosse SD, Robbins JM, et al. Health state preference scores of children with spina bifida and their caregivers. Qual Life Res. 2005;14:1087\u201398.","journal-title":"Qual Life Res"},{"key":"1540_CR35","doi-asserted-by":"publisher","first-page":"A725","DOI":"10.1016\/j.jval.2017.08.1962","volume":"20","author":"R Thompson","year":"2017","unstructured":"Thompson R, Vaidya S, Teynor M. The utility of different approachs to developing health utilities data in childhood rare diseases and; a case study in spinal muscular atrophy (SMA). Value Health. 2017;20:A725\u20136.","journal-title":"Value Health"},{"key":"1540_CR36","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2165\/00019053-200624120-00005","volume":"24","author":"U Ravens-Sieberer","year":"2006","unstructured":"Ravens-Sieberer U, Erhart M, Wille N, et al. Generic health-related quality-of-life assessment in children and adolescents. Pharmacoeconomics. 2006;24:1199\u2013220.","journal-title":"Pharmacoeconomics"},{"key":"1540_CR37","unstructured":"International Society for Pharmacoeconomics and Outcomes Research. Valuing HRQoL of children and adolescents in economic evaluation (pediatric utilities). 2025.  https:\/\/www.ispor.org\/member-groups\/task-forces\/Valuing-HRQoL-of-Children-Adolescents-in-Economic-Models"},{"key":"1540_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-020-00723-1","volume":"12","author":"F Landeiro","year":"2020","unstructured":"Landeiro F, Mughal S, Walsh K, et al. Health-related quality of life in people with predementia Alzheimer\u2019s disease, mild cognitive impairment or dementia measured with preference-based instruments: a systematic literature review. Alzheimers Res Ther. 2020;12:154.","journal-title":"Alzheimers Res Ther"},{"key":"1540_CR39","doi-asserted-by":"publisher","first-page":"e166","DOI":"10.1002\/gps.4771","volume":"33","author":"F Yang","year":"2018","unstructured":"Yang F, Dawes P, Leroi I, et al. Measurement tools of resource use and quality of life in clinical trials for dementia or cognitive impairment interventions: a systematically conducted narrative review. Int J Geriatr Psychiatry. 2018;33:e166\u201376.","journal-title":"Int J Geriatr Psychiatry"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01540-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01540-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01540-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:45:06Z","timestamp":1768319106000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01540-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1540"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01540-w","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors provide\u00a0this consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Becky Pennington is a member of the National Institute for Health and Care Excellence (NICE) Technology Appraisal Committee A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human participants performed by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All data used in this manuscript are available in the public domain in the sources referenced.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data and\/or Code availability"}},{"value":"Becky Pennington conceived the idea for the work and drafted the initial version of the manuscript. Sarah Davis and Holly Cranmer helped to identify case studies, checked calculations, provided critical feedback and insightful suggestions in discussion and on the manuscript, and reviewed and revised the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contribution statements"}}]}}